1
Kiyoto Sumio, Nishikawa Motoaki, Iwami Morita, Terano Hiroshi, Kohsaka Masanobu, Imanaka Hiroshi: Biologically active ws 6049 substances, a process for the production thereof and their pharmaceutical compositions.. Fujisawa Pharmaceutical Co, November 30, 1983: EP0095154-A1 (64 worldwide citation)

Biologically active WS 6049 substances obtainable by culturing a strain belonging to the genus Actinomadura in an aqueous nutrient medium under aerobic conditions and recovering WS 6049-A substance and/or WS 6049-B substance. The invention also relates to a process for preparing the new substances a ...


2
Oohata Nobutaka, Nishikawa Motoaki, Kiyoto Sumio, Takase Shigehiro, Hemmi Keiji, Murai Hidetsugu, Okuhara Masakuni: Anthraquinone derivatives and preparation thereof.. Fujisawa Pharmaceutical Co, January 2, 1991: EP0405421-A2 (29 worldwide citation)

A compound of the formula: wherein R is hydrogen, hydroxy or acyloxy, R is hydrogen or acyl, R is acyl, R is hydrogen or acyl, R is hydrogen or acyl, R is hydrogen or acyl, and R is hydrogen or acyl, and pharmaceutically acceptable salt thereof, processes for the preparation and pharmaceutical compo ...


3
Kino Tohru, Nishikawa Motoaki, Ezaki Masami, Kiyoto Sumio, Okuhara Masakuni, Takase Shigehiro, Okada Satoshi, Shigematsu Nobuharu: Peptide derivatives.. Fujisawa Pharmaceutical Co, October 11, 1989: EP0336230-A2 (6 worldwide citation)

A compound of the formula wherein the symbols define certain groups or atoms, processes for their preparation and pharmaceutical compositions comprising them as an active ingredient in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient. The invention also co ...


4
Nishikawa Motoaki, Iwami Morita, Yoshida Keizo, Kohsaka Masanobu: Ws 7739 substances, their preparation and pharmaceutical composition containing the same.. Fujisawa Pharmaceutical Co, May 22, 1985: EP0142121-A2 (2 worldwide citation)

New biologically active substances - called WS 7739 - having pharmacological activity are prepared by fermentation of a strain belonging to the genus Streptomyces, e.g. Streptomyces phaeofaciens subsp. matsuenensis no. 7739 FERM BP 660 in a nutrient medium containing sources of assimilable carbon an ...


5
Kino Tohru, Nishikawa Motoaki, Ezaki Masami, Kiyoto Sumio, Okuhara Masakuni, Takase Shigehiro, Okada Satoshi, Shigematsu Nobuharu: Ws-9326a, ws-9326b and their derivatives.. Fujisawa Pharmaceutical Co, August 9, 1989: EP0327009-A1 (1 worldwide citation)

This application relates to new compounds called WS-9326A, WS-9326B, and their derivatives having valuable pharmaceutical properties and which are obtainable by culturing a WS-9326A and/or WS-9326B producing strain belonging to the genus Streptomyces in nutrient medium and recovering such compounds ...


6
Murai Hidetsugu, Ueda Hirotsugu, Hayashi Kenichi, Okamoto Masanori, Kiyoto Sumio, Goto Toshio, Nishikawa Motoaki, Tsurumi Yasuhisa, Takase Shigehiro, Okuhara Masakuni: Ws75624 substances from saccharothrix strain. Fujisawa Pharmaceutical Co, May 18, 1994: GB2272435-A (1 worldwide citation)

WS75624 substances and salts thereof (having the physico-chemical properties defined herein) am provided. A process for producing these substances or salts thereof is described and which comprises culturing a WS75624 substance-producing strain belonging to the genus Saccharothrix in a nutrient mediu ...


7
Morimoto Hiroshi, Nishikawa Motoaki, Tsukada Hideo, Kakiuchi Takeharu: Ocular function examination drug and method for assaying ocular function using the same. Astellas Pharma, Hamamatsu Photonics, August 3, 2006: JP2006-199615 (1 worldwide citation)

PROBLEM TO BE SOLVED: To provide an ocular function examination drug capable of assaying ocular functions including hydatoid issue and retinal cell activity spacially(planarly or three-dimensionally), in high sensitivity and in real time in vivo, and to provide a non-invasive and animal-reusable met ...


8
Kiyoto Sumio, Nishikawa Motoaki, Imanaka Hiroshi, Kohsaka Masanobu, Terano Hiroshi, Iwami Morita: Substances sw6049 ayant une activite biologique, procede de production et composes pharmaceutiques les contenant, Biologically active ws 6049 substances, a process for the production thereof and their pharmaceutical compositions. Fujisawa Pharmaceutical, SWABEY MITCHELL HOULE MARCOUX & SHER, August 19, 1986: CA1209935

ABSTRACT OF THE DISCLOSURE BIOLOGICALLY ACTIVE WS 6049 SUBSTANCES, A PROCESS FOR THE PRODUCTION THEREOF AND THEIR PHARMACEUTICAL COMPOSITIONS WS 6049 substances having antitumor activity are described. The substances may be produced by culturing a strain belonging to the genus Actinomadura, which is ...


9
Kino Tohru, Okada Satoshi, Ezaki Masami, Nishikawa Motoaki, Kiyoto Sumio, Shigematsu Nobuharu, Takase Shigehiro, Okuhara Masakuni: Derives peptidiques utilises pour le traitement et la prevention de lasthme et dautres affections similaires, Peptide derivatives for the treatment and prevention of asthma and the like. Fujisawa Pharmaceutical, OGILVY RENAULT SENCRLSRL, May 23, 1995: CA1335662

Peptide derivatives of the formula: Imagewherein R1 is hydrogen or an acyl group; R2 is hydroxy andR3 is carboxy or protected carboxy, orR2 and R3 are linked together to represent agroup of the formula : Image ;R4 is hydroxy or protected hydroxy;R5 is hydroxy or protected hydroxy;R6 is hydroxy, prot ...


10
Kino Tohru, Nishikawa Motoaki, Okada Satoshi, Ezaki Masami, Shigematsu Nobuharu, Kiyoto Sumio, Okuhara Masakuni, Takase Shigehiro: Ws-9326a, ws-9326b et leurs derives, Ws-9326a, ws-9326b and their derivatives. Fujisawa Pharmaceutical, SWABEY OGILVY RENAULT, April 23, 1996: CA1338261

Compounds identified as WS-9326A and WS-9326Bwhich are obtained by culturing a WS-9326A and/or WS-9326Bproducing strain belonging to the genus Streptomyces in anutrient medium. Salts thereof can also be obtained.These compounds or salts thereof can also be acylated toproduce acyl derivatives. These ...